Abstract
Purpose: The purpose of this study was to investigate B7 homolog 3 (B7-H3) expression patterns and define its associations with programmed cell-death ligand 1 (PD-L1), patholo-gical features, and survival in patients with cervical cancer. Patients and Methods: Immunohistochemical staining was used to investigate B7-H3 and PD-L1 expression in tissue microarrays from 552 patients with stage IB1 and IIA1 cervical cancer, including 406 with squamous cell carcinoma and 146 with endocervical adenocarcinoma. Results: B7-H3 was expressed in the tumor cells (TCs) of 32.1% of the samples as well as in the stromal cells of 92.9% of the specimens. B7-H3 was co-expressed with PD-L1 in 21.0% of the samples, while only one or the other was expressed in 41.7% of the samples. B7-H3 expression in TCs was more frequent in squamous cell carcinoma, PD-L1-positive samples, and tissues from patients with lymph node metastasis; moreover, its expression was an independent predictor of shorter survival. Conclusion: B7-H3 positivity in TCs is a promising prognostic biomarker, and targeting B7-H3 alone or in combination with PD-1/PD-L1 may be a potential immunotherapeutic strategy for patients with cervical cancer.
Author supplied keywords
Cite
CITATION STYLE
Zhang, Q., Zong, L., Zhang, H., Xie, W., Yang, F., Sun, W., … Zhang, Y. (2021). Expression of B7-H3 correlates with PD-L1 and poor prognosis in patients with cervical cancer. OncoTargets and Therapy, 14, 4275–4283. https://doi.org/10.2147/OTT.S318082
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.